

Supplement File 3

Tumor stage distribution between the ERAS and the Control Group

	Entire cohort (N=127)	ERAS (n=66)	Control (n=58)
<u>Clinical stage</u>			
SCC	113	60	53
Stage 0	3 2.65%	1 1.67%	2 3.78%
Stage I	9 7.96%	5 8.33%	4 7.55%
Stage II	23 20.35%	13 21.67%	9 16.98%
Stage III	74 65.49%	37 61.67%	35 66.04%
Stage IVA	7 5.51%	4 6.67%	3 5.66%
Stage IVB	0 0%	0 0%	0 0%
<i>Others tumor type</i>	11	6	5
Stage 0	1 9.09%	1 16.67%	0 0%
Stage I	2 18.18%	0 0%	2 40%
Stage IIA	2 18.18%	1 16.67%	1 20%
Stage IIB	3 27.27%	2 33.33%	1 20%
Stage III	3 27.27%	2 33.33%	1 20%
Stage IVA	0 0%	0 0%	0 0%
Stage IVB	0 0%	0 0%	0 0%
<u>Pathology stage</u>			
No preoperative CCRT			
SCC	28	13	15
Stage 0	2 7.14%	1 7.69%	1 6.67%
Stage IA	0 0%	0 0%	0 0%
Stage IB	12 42.86%	5 38.46%	7 46.67%
Stage IIA	4 14.29%	1 7.69%	3 20%
Stage IIB	3 10.71%	2 15.38%	1 6.67%
Stage IIIA	1 3.57%	1 7.69%	0 0%
Stage IIIB	4 14.29%	2 15.38%	2 13.33%
Stage IVA	2 7.14%	1 7.69%	1 6.67%
Stage IVB	0 0%	0 0%	0 0%
<i>Others tumor type</i>	9	4	5
Stage 0	2 22.22%	1 25%	1 20%
Stage IA	1 11.11%	0 0%	1 20%
Stage IB	2 22.22%	1 25%	1 20%
Stage IC	0 0%	0 0%	0 0%

Stage IIA	2	22.22%	1	25%	1	20%
Stage IIB	0	0%	0	0%	0	0%
Stage IIIA	0	0%	0	0%	0	0%
Stage IIIB	1	11.11%	1	25%	0	0%
Stage IVA	1	11.11%	0	0%	1	20%
Stage IVB	0	0%	0	0%	0	0%

Received preoperative CCRT

SCC	85		47		38	
Stage 0	0	0%	0	0%	0	0%
Stage I	51	60%	27	57.45%	24	63.16%
Stage II	11	12.94%	8	17.02%	3	7.89%
Stage IIIA	11	12.94%	8	17.02%	3	7.89%
Stage IIIB	9	10.59%	3	6.38%	6	15.79%
Stage IVA	3	3.53%	1	2.13%	2	5.26%
Stage IVB	0	0%	0	0%	0	0%

<i>Others tumor type</i>	2		2		0	
Stage 0	0	0%	0	0%	0	0%
Stage I	0	0%	0	0%	0	0%
Stage II	0	0%	0	0%	0	0%
Stage IIIA	1	50%	1	50%	0	0%
Stage IIIB	1	50%	1	50%	0	0%
Stage IVA	0	0%	0	0%	0	0%
Stage IVB	0	0%	0	0%	0	0%

Clinical stage and pathologic Stage, 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction